TP53 and breast carcinoma: When combined with chemotherapy, APR-246 induced complete remission in approximately 47% of TP53-mutant patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), providing a compelling rationale for translational application in breast cancer (16).